Literature DB >> 27426299

Design and synthesis of aminothiazole modulators of the gamma-secretase enzyme.

Kevin D Rynearson1, Ronald N Buckle2, Keith D Barnes2, R Jason Herr2, Nicholas J Mayhew2, William D Paquette2, Samuel A Sakwa2, Phuong D Nguyen1, Graham Johnson3, Rudolph E Tanzi4, Steven L Wagner5.   

Abstract

The design and construction of a series of novel aminothiazole-derived γ-secretase modulators is described. The incorporation of heterocyclic replacements of the terminal phenyl D-ring of lead compound 1 was conducted in order to align potency with favorable drug-like properties. γ-Secretase modulator 28 displayed good activity for in vitro inhibition of Aβ42, as well as substantial improvement in ADME and physicochemical properties, including aqueous solubility. Pharmacokinetic evaluation of compound 28 in mice revealed good brain penetration, as well as good clearance, half-life, and volume of distribution which collectively support the continued development of this class of compounds.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Alzheimer’s disease; Aminothiazoles; γ-Secretase modulators

Mesh:

Substances:

Year:  2016        PMID: 27426299     DOI: 10.1016/j.bmcl.2016.07.011

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  5 in total

1.  Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators.

Authors:  Kevin D Rynearson; Ronald N Buckle; R Jason Herr; Nicholas J Mayhew; Xinchao Chen; William D Paquette; Samuel A Sakwa; Jinhai Yang; Keith D Barnes; Phuong Nguyen; William C Mobley; Graham Johnson; Juinn H Lin; Rudolph E Tanzi; Steven L Wagner
Journal:  Bioorg Med Chem       Date:  2020-09-01       Impact factor: 3.641

Review 2.  Recent developments of small molecule γ-secretase modulators for Alzheimer's disease.

Authors:  Shekar Mekala; Grady Nelson; Yue-Ming Li
Journal:  RSC Med Chem       Date:  2020-08-27

3.  Soluble Gamma-secretase Modulators Attenuate Alzheimer's β-amyloid Pathology and Induce Conformational Changes in Presenilin 1.

Authors:  Frank Raven; Joseph F Ward; Katarzyna M Zoltowska; Yu Wan; Enjana Bylykbashi; Sean J Miller; Xunuo Shen; Se Hoon Choi; Kevin D Rynearson; Oksana Berezovska; Steven L Wagner; Rudolph E Tanzi; Can Zhang
Journal:  EBioMedicine       Date:  2017-09-04       Impact factor: 8.143

4.  NGP 555, a γ-Secretase Modulator, Lowers the Amyloid Biomarker, Aβ42, in Cerebrospinal Fluid while Preventing Alzheimer's Disease Cognitive Decline in Rodents.

Authors:  Maria Z Kounnas; Courtney Lane-Donovan; Dan W Nowakowski; Joachim Herz; William T Comer
Journal:  Alzheimers Dement (N Y)       Date:  2017-01

5.  Preclinical validation of a potent γ-secretase modulator for Alzheimer's disease prevention.

Authors:  Kevin D Rynearson; Moorthi Ponnusamy; Olga Prikhodko; Yuhuan Xie; Can Zhang; Phuong Nguyen; Brenda Hug; Mariko Sawa; Ann Becker; Brian Spencer; Jazmin Florio; Michael Mante; Bahar Salehi; Carlos Arias; Douglas Galasko; Brian P Head; Graham Johnson; Jiunn H Lin; Steven K Duddy; Robert A Rissman; William C Mobley; Gopal Thinakaran; Rudolph E Tanzi; Steven L Wagner
Journal:  J Exp Med       Date:  2021-04-05       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.